Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18647926 | 0.93 | TLR8 (0.42) | LMNAGAATP53TLR8TLR7 | |
| SCHEMBL22459185 | 0.91 | TLR8 (0.41) | LMNAGAATP53TLR8TLR7 | |
| SCHEMBL19570217 | 0.91 | TLR8 (0.41) | LMNAGAATP53TLR8TLR7 | |
| SCHEMBL18898429 | 0.91 | TLR8 (0.41) | LMNAGAATP53TLR8TLR7 | |
| SCHEMBL8237746 | 0.88 | LMNA (0.44) | LMNAGAASMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL14759391 | 0.80 | LMNA (0.42) | LMNAGAATLR8SMN1; SMN2CRHBP | |
| SCHEMBL2238495 | 0.79 | LMNA (0.48) | LMNAGAASMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL3189527 | 0.78 | TLR8 (0.42) | GAATP53TLR8TLR7ALDH1A1 | |
| SCHEMBL2056168 | 0.78 | — | — | |
| SCHEMBL1580004 | 0.77 | LMNA (0.43) | LMNAGAASMN1; SMN2CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026926-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| US-20190216782-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2019-07-18 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026926-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | LMNA 2150/4885GAA 3664/4885TP53 273/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | LMNA 1347/4885GAA 887/4885TP53 3035/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | LMNA 4717/4885GAA 566/4885TP53 214/4885 |
| US-20190216782-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | LMNA 2533/4885GAA 3620/4885TP53 361/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | LMNA 4046/4885GAA 759/4885TP53 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.